Background. The combination of Rituximab plus chemotherapy (CT) is more effective than
CT alone in the treatment of high grade NHL. Objective. To report the long-term follow-up of …

Abstract Abstract 3976 Methotrexate (MTX), a classical anti-folate drug, has been used in the
treatment of various hematological malignancies. Since MTX prevents tumor cells from …

FK228 (romidepsin) and suberoylanilide hydroxamic acid (vorinostat) are histone
deacetylase inhibitors (HDACi) approved by the US Food and Drug Administration for …

Abstract The phase II PROPEL (Pralatrexate in Patients with Relapsed or Refractory
Peripheral T-cell Lymphoma) trial was the first of its kind devoted to a population of patients …

Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We
demonstrated in vitro synergism between histone deacetylase inhibitors and DNA …

Background Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis,
particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue …

Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin
in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a …

Purpose: Methotrexate is known to synergize with cytarabine [1-β-d-
arabinofuranosylcytosine (ara-C)] in a schedule-dependent manner. The purpose of this …

Purpose To investigate the impact of 5-formyltetrahydrofolate on the activities of pralatrexate,
as compared to methotrexate (MTX), in vitro. Methods Cells were exposed to (6 S) 5 …

Purpose Pralatrexate is a new generation antifolate treatment agent used for the treatment of
relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general …